¿Theoretical and Clinical Geropharmacology¿

1. Senotherapeutics: Milestones, innovations, and future prospectsUfuk Çakatay, Erdem Atasever and Mehmet Can Atayik2. Game Changer: Navigating between challenges and hopes in GeropharmacologyQian Chen, Lindon Young, Reid Hartman, Lidia Dankiv, Emily Yan and Robert Barsotti3. Next-Gen Senotherapeutics: AI/ML-driven strategies for aging and age-related disordersKavitha Thirumurugan, Prashanth S. Javali, Subhajit Sarkar, Ashish Kumar, Sree Varshini R and Jose Mathew D4. Pharmacological frontiers in senescence: Transforming senescence with drug repurposing :Andleeb Shahzadi, Sibel Ozyazgan and Ufuk Çakatay5. Pharmacological potential of calorie restriction mimetics in mitigating brain agingAbhishek Kumar Singh6. Isothiocyanates from cruciferous plants as geroprotectorsVolodymyr I. Lushchak7. Cellular parabiosis as a senotherapeutic approachIlhan Onaran and Sevide Sencan8. Molecular imaging for senescent cells-targeted therapeutics in aging and age-related diseasesPeili Cen9. Mitochondria-associated membranes (MAMs) in age-related heart diseases, role of endoplasmic reticulum stressAlejandro Silva-Palacios10. Cellular senescence and senotherapeutics in cardiovascular diseasesArttatrana Pal11. Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patientsTamer Cebe and Fatih Kizilyel12. Geropharmacology and gastrointestinal surgeryAnil Orhan13. Oxygen-ozone adjunct therapy in aging and senescence-related disorders. State of artSalvatore Chirumbolo, Giovanni Ricevuti, Marianno Franzini and Francesco Vaiano14. Polypharmacy-induced changes in the oral mucosa and jawbone in elderlyMehmet Yaltirik, Kaan Erisildar and Sabahat Zeynep Yey Özkeskin15. Senotherapeutic approach to age-related endocrine diseasesGülnur Andican and Seydanur Turgut16. Polypharmacy as a reason for misinterpreting laboratory results in the elderly.Ibrahim Murat Bolayirli